Skip To Main Content
Innocent Gerald Asiimwe on Muck Rack

Innocent Gerald Asiimwe

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Innocent Gerald

Contact Innocent Gerald, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Advancing Pharmacometrics in Africa: Insights and Perspectives From the 2025 Pharmacometrics Africa Conference

|
By Babatunde Ayodeji Adeagbo, Innocent Gerald Asiimwe, Linda Chaba
| Wiley Online Library Verified
The field of PMX in Africa has evolved tremendously in the last two decades, from a small group in Durban, South Africa, to training workshops in several African countries focusing on addressing critical public health needs.
Open in Who Shared Issue with article?

Postmarketing Assessment of Antibody-Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach

|
By Samer Mouksassi, Innocent Gerald Asiimwe, Nour Chtiba, Raimund M. Peter
| Wiley Online Library Verified
What is the current knowledge on the topic? ○ Antibody–drug conjugates (ADCs) are a promising class of targeted cancer therapies that require careful dose optimization to maximize effectiveness and minimize side effects. What question did this study address? ○ Can a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach be used to assess the benefit–risk profiles of ADCs? What does this study add to our knowledge?
Open in Who Shared Issue with article?

UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta‐Analysis

|
By Innocent Gerald Asiimwe, Sudeep P Pushpakom, Carlo Palmieri, Cinzia Dello Russo
| Wiley Online Library Verified
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Sacituzumab Govitecan (SG), a humanized antibody-drug conjugate targeting the surface glycoprotein Trop-2, has been engineered to enhance the intra-tumor delivery of SN-38 and reduce its systemic toxicity. However, toxicity closely resembling those of irinotecan emerged during drug development suggesting the involvement of genetic variation in UGT1A1.
Open in Who Shared Issue with article?
See all 3 articles